A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)
AZUR-1 will evaluate the efficacy of dostarlimab immunotherapy in dMMR/MSI-H RC. Utilizing novel aspects including long follow-up of all patients and standardization of clinical response assessment, this study will provide international multicentric data to evaluate tumor response in an immunotherapy setting and new evidence on long-term outcomes.
Authors
- Naureen Starling (ORCID: https://orcid.org/0000-0002-1496-6792)
- Lisa Salvatore (ORCID: https://orcid.org/0000-0003-3864-0719)
- Volker Heinemann (ORCID: https://orcid.org/0000-0002-1349-3321)
- Andrea Cercek (ORCID: https://orcid.org/0000-0002-5054-8192)
- Hideaki Bando (ORCID: https://orcid.org/0000-0001-5041-2765)
- Jean‐Baptiste Bachet (ORCID: https://orcid.org/0000-0003-4337-286X)
- Zsolt Szíjgyártó (ORCID: https://orcid.org/0000-0002-1086-4094)
- Eric Chen (ORCID: https://orcid.org/0000-0002-9193-1518)
- Jaume Capdevila
- Sean O'donnell
- Lauren Harfst
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Hebron University (PS)
- Royal Marsden NHS Foundation Trust (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Providence College (US)
- Age UK (GB)
- Agostino Gemelli University Polyclinic (IT)
- Princess Margaret Cancer Centre (CA)
- LMU Klinikum (DE)
- Sorbonne Université (FR)
- Pitié-Salpêtrière Hospital (FR)
- National Cancer Center Hospital East (JP)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Clinical Colorectal Cancer
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1016/j.clcc.2025.02.003
- Citations
- 2
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.09